BSGM · Biosig Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $13.0K | $14.0K | - | $1.0K | $13.0K | $14.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | $6.0K | $19.0K | $6.0K | - | $156.0K | $342.0K | $238.0K | - |
| SG&A | $34.25M | - | $4.62M | $19.79M | $2.96M | - | $2.76M | $4.91M | $2.88M | - |
| Total Operating Expenses | $35.75M | - | $6.11M | $20.36M | $2.98M | - | $2.95M | $5.30M | $3.45M | - |
| D&A | $1.49M | - | $1.49M | $49.0K | $78.0K | - | $31.0K | $49.0K | $78.0K | - |
| Operating Income | ($35.75M) | - | ($6.11M) | ($20.36M) | ($2.98M) | - | ($2.95M) | ($5.29M) | ($3.44M) | - |
| Interest Expense | $12.18M | - | - | - | - | - | - | - | - | - |
| Income Tax | ($565.0K) | - | ($765.0K) | - | - | - | - | - | - | - |
| Net Income | ($46.69M) | - | ($15.58M) | ($20.37M) | ($2.81M) | - | ($1.91M) | ($3.92M) | ($3.40M) | - |
| EPS - Basic | ($0.27) | - | ($0.47) | ($0.74) | ($0.14) | - | ($0.12) | ($1.58) | ($0.36) | - |
| EPS - Diluted | ($0.27) | - | ($0.47) | ($0.74) | ($0.14) | - | ($0.12) | ($0.30) | ($0.36) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.86M | $20.30M | $11.04M | $2.82M | $3.73M | $142.0K | $615.0K | $2.10M | $416.0K | $200.0K |
| Accounts Receivable | - | - | - | - | $109.0K | $109.0K | $81.0K | $54.0K | $14.0K | $24.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $45.90M | $71.89M | $14.99M | $3.00M | $3.99M | $344.0K | $848.0K | $2.39M | $740.0K | $528.0K |
| Total Assets | $173.32M | $187.54M | $130.51M | $109.72M | $4.42M | $842.0K | $1.42M | $3.11M | $1.59M | $1.80M |
| Current Liabilities | $3.30M | $42.79M | $125.60M | $113.20M | $1.68M | $2.26M | $1.70M | $2.98M | $5.23M | $4.58M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $13.97M | $54.22M | $137.34M | $113.20M | $1.68M | $2.26M | $1.70M | $2.99M | $5.79M | $4.68M |
| Stockholders' Equity | $158.99M | $133.19M | ($6.96M) | ($3.62M) | $2.60M | ($1.54M) | ($405.0K) | ($6.0K) | ($4.32M) | ($3.02M) |
| Retained Earnings | ($764.81M) | ($718.12M) | ($294.11M) | ($278.53M) | ($258.16M) | ($255.34M) | ($254.25M) | ($252.33M) | ($248.42M) | ($245.01M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.18M) | - | - | - | ($1.11M) | - | - | - | ($1.31M) | - |
| Investing Cash Flow | ($1.50M) | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | ($1.64M) | - | - | - | $4.70M | - | - | - | $1.54M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -156653.8% | -21314.3% | - | -295000.0% | -40707.7% | -24550.0% | - |
| EBITDA margin | - | - | - | -156276.9% | -20757.1% | - | -291900.0% | -40330.8% | -23992.9% | - |
| Net margin | - | - | - | -156707.7% | -20085.7% | - | -191400.0% | -30115.4% | -24300.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | 146.2% | 42.9% | - | 15600.0% | 2630.8% | 1700.0% | - |
| SG&A / Revenue | - | - | - | 152246.2% | 21121.4% | - | 276300.0% | 37800.0% | 20585.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.9% | - | -11.9% | -18.6% | -63.6% | - | -135.0% | -126.0% | -214.1% | - |
| Return on equity | -29.4% | - | 223.9% | 563.2% | -107.9% | - | 472.6% | 65250.0% | 78.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 13.90 | 1.68 | 0.12 | 0.03 | 2.37 | 0.15 | 0.50 | 0.80 | 0.14 | 0.12 |
| Quick ratio | 13.90 | 1.68 | 0.12 | 0.03 | 2.37 | 0.15 | 0.50 | 0.80 | 0.14 | 0.12 |
| Cash ratio | 2.08 | 0.47 | 0.09 | 0.02 | 2.22 | 0.06 | 0.36 | 0.71 | 0.08 | 0.04 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2.9x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.41 | -18.75 | -30.33 | 1.70 | -0.55 | -3.50 | -517.83 | -0.37 | -0.60 |
| Liabilities / Assets | 0.08 | 0.29 | 1.05 | 1.03 | 0.38 | 2.69 | 1.20 | 0.96 | 3.65 | 2.61 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 2842d | - | 29565d | 1516d | 365d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | 0.0% | 0.0% | - | 0.0% | - | 180.0% | - |
| Revenue CAGR (3y) | - | - | - | 17.6% | 20.5% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -1097.9% | - | -107.2% | -284.8% | 13.2% | - | 27.2% | 51.5% | 53.5% | - |
| Net income growth (YoY) | -1560.5% | - | -714.2% | -420.4% | 17.3% | - | 58.1% | 64.7% | 53.6% | - |
| EPS growth (YoY) | -92.9% | - | -291.7% | -146.7% | 61.1% | - | -100.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 6003.1% | - | -1618.3% | -60183.3% | - | 48.8% | 65.1% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$40.0K totalCorporate$40.0K · 100.0%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing BioSig Technologies against the 5 most active filers in the same SIC group.